Self-reactive antibodies, or autoantibodies, against two proteins — homeostatic iron regulator, or HFE, and synaptotagmin 5, known as SYT5 — appear to be linked to a higher risk of relapse among people with ANCA-associated vasculitis (AAV), according to a new study. These findings suggest that the presence of abnormal…
Read more
A new Phase 3 clinical trial is recruiting children and adolescents with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the most common types of ANCA-associated vasculitis (AAV), to test Tavneos (avacopan) in combination with rituximab or cyclophosphamide. That’s according to a financial update released by…
Fasenra (benralizumab) has been granted approval in the European Union as an add-on treatment for adults with relapsing or treatment-resistant eosinophilic granulomatosis with polyangiitis, or EGPA, a rare type of ANCA-associated vasculitis (AAV). The clearance of Fasenra, “with its convenient, single-monthly injection is a positive step forward…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
